# Benjamin S Braun

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 25 papers | 1,715 citations | 566801 15 h-index | 713013 21 g-index |
| 25 all docs | 25 docs citations | 25 times ranked | 2929 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nature Genetics, 2010, 42, 794-800. | 9.4 | 308 |
| 2 | Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 597-602. | 3.3 | 279 |
| 3 | Targeting oncogenic Ras signaling in hematologic malignancies. Blood, 2012, 120, 3397-3406. | 0.6 | 171 |
| 4 | Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood, 2004, 103, 4243-4250. | 0.6 | 162 |
| 5 | Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood, 2011, 117, 2022-2032. | 0.6 | 132 |
| 6 | Tissue-Specific Oncogenic Activity of KRASA146T. Cancer Discovery, 2019, 9, 738-755. | 7.7 | 127 |
| 7 | K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood, 2007, 109, 3945-3952. | 0.6 | 103 |
| 8 | Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells. PLoS Biology, 2009, 7, e1000059. | 2.6 | 89 |
| 9 | Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nature Communications, 2017, 8, 2127. | 5.8 | 75 |
| 10 | Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. Blood, 2015, 125, 516-524. | 0.6 | 69 |
| 11 | Targeting Ras in Myeloid Leukemias. Clinical Cancer Research, 2008, 14, 2249-2252. | 3.2 | 57 |
| 12 | Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia. Cancer Research, 2019, 79, 2339-2351. | 0.4 | 55 |
| 13 | Fusion driven JMML: a novel CCDC88Câ€“FLT3 fusion responsive to sorafenib identified by RNA sequencing. Leukemia, 2020, 34, 662-666. | 3.3 | 27 |
| 14 | A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Research, 2017, 77, 5706-5711. | 0.4 | 22 |
| 15 | Paroxysmal cold hemoglobinuria successfully treated with complement inhibition. Blood Advances, 2019, 3, 3575-3578. | 2.5 | 19 |
| 16 | KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice. JCI Insight, 2020, 5, . | 2.3 | 10 |
| 17 | The sum is greater than the FGFR1 partner. Cancer Cell, 2004, 5, 203-204. | 7.7 | 4 |
| 18 | The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment. Haematologica, 2021, 106, 2242-2245. | 1.7 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Pediatric malignancies: update on sarcomas and leukemia development in children. Current Opinion in Genetics and Development, 2009, 19, 92-96. | 1.5 | 1 |
| 20 | Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia. Blood Advances, 2021, 5, 3587-3591. | 2.5 | 1 |
| 21 | The PI3K Inhibitor GDC-0941 Attenuates Disease in a KrasG12D Mouse Model of CMML and JMML.. Blood, 2012, 120, 2862-2862. | 0.6 | 1 |
| 22 | The SPS Affair: A Complex Tale of Illicit Proliferation. Cancer Cell, 2009, 16, 87-88. | 7.7 | 0 |
| 23 | Traxtile: Interactive editing of cell tracks in time-lapse images. BioTechniques, 2015, 59, 82-6. | 0.8 | 0 |
| 24 | Intracellular Signals as Molecular Biomarkers for Therapeutic Responses in Kras Mutant Myeloid Cells.. Blood, 2007, 110, 2196-2196. | 0.6 | 0 |
| 25 | Leukemogenic K-RasG12D Induces Cell Cycle Entry and Clonal Dominance in Hematopoietic Stem Cells.. Blood, 2007, 110, 778-778. | 0.6 | 0 |